Filing summary
Entity discrepancy: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q, not Oruka Therapeutics, Inc. It covers the quarter ended September 30, 2018 and was signed November 14, 2018. The interim financial statements are unaudited.
Business context and reporting period
ARCA is a development-stage biopharmaceutical company focused on genetically targeted cardiovascular therapies. Its lead candidate, Gencaro (bucindolol), is being developed for atrial fibrillation in heart-failure patients with a specified genotype. The company reported no revenue to date. It completed its 267-patient Phase 2B GENETIC-AF trial and began IND-enabling work on AB171, a potential candidate for peripheral arterial disease and heart failure.
Financial results and liquidity
| Metric | Three months ended September 30, 2018 | Nine months ended September 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $0.740 million | $3.614 million | $3.488 million and $11.242 million |
| General and administrative expense | $0.922 million | $2.977 million | $0.987 million and $3.173 million |
| Net loss | $1.593 million | $6.444 million | $4.433 million and $14.293 million |
| Net loss per share, basic and diluted | $0.11 | $0.47 | $0.39 and $1.43 |
| Operating cash used | Not provided for the quarter | $6.901 million | $13.276 million |
At September 30, 2018, cash and cash equivalents were $8.056 million, with no marketable securities, versus total cash and marketable securities of $11.752 million at December 31, 2017. Current assets were $8.392 million and current liabilities $0.978 million; total liabilities were $0.982 million and stockholders’ equity $7.463 million. Interest expense was $8,000 for the nine-month period. No conventional debt balance is separately shown; the company reported vendor-financing principal repayments of $206,000 during the period.
Cash declined $646,000 over the first nine months. Financing provided $3.209 million net, principally from equity issuance, while investing provided $3.046 million, primarily from marketable-security maturities. The company said cash would fund operations at its projected cost structure through the end of Q1 2019, but concluded substantial doubt existed about its ability to continue as a going concern for one year after issuance of the statements.
Material changes versus prior comparable periods
- Third-quarter net loss narrowed to $1.593 million from $4.433 million; nine-month net loss narrowed to $6.444 million from $14.293 million.
- R&D expense fell substantially because the GENETIC-AF trial was completed and related clinical and manufacturing costs did not recur. Management expected 2018 R&D expense to be below 2017.
- G&A expense was broadly stable; management expected it to remain consistent with 2017.
- Cash and marketable securities fell by $3.696 million from year-end 2017. The company had used all shares available under its existing at-the-market offering.
- Common shares outstanding increased from 11.775 million at year-end 2017 to 13.924 million at September 30, 2018.
Outlook, developments, and risks
- The FDA said a single pivotal Phase 3 trial might be sufficient to support a Gencaro application. However, in late October 2018 the FDA issued a “No Agreement” letter on the company’s Special Protocol Assessment request and agreed to reconsider it after further correspondence. ARCA requested a meeting, expected in December if granted; timing of an FDA decision was uncertain.
- Further development of Gencaro, AB171, and continued operations depended on additional financing or a strategic transaction. Failure to obtain funding could lead to delays, reduced development, or discontinued operations.
- Nasdaq granted an extension through April 8, 2019 to regain compliance with the $1.00 minimum bid-price requirement. Stockholders authorized a possible reverse split at a ratio between 1-for-3 and 1-for-20; the board had not selected a ratio.
- GENETIC-AF showed a similar overall treatment benefit for Gencaro and metoprolol, with trends favoring Gencaro in certain subgroups. The filing describes these findings as supportive of further development, not proof of efficacy for approval.
- Other material risks include clinical and regulatory uncertainty, reliance on third-party manufacturers and clinical vendors, the need for a companion genetic test, potential dilution from future financing, and limited resources for commercialization. Management reported disclosure controls were effective at a reasonable level of assurance and no material change in internal control over financial reporting during the quarter. No legal proceedings were reported.
Investor verification priorities
- Confirm the issuer: the source filing is for ARCA biopharma, Inc., despite the request identifying Oruka Therapeutics, Inc.
- Check subsequent FDA correspondence and whether the Gencaro SPA was reconsidered or a Phase 3 protocol agreed.
- Verify the company’s financing, cash runway, and any strategic transaction after the stated Q1 2019 runway estimate.
- Check Nasdaq bid-price compliance, any reverse split, and resulting share count and dilution.
- Review the full filing and later clinical disclosures for the distinction between overall GENETIC-AF results and subgroup or post-hoc analyses.